DMD: Eteplirsen-Treated Boys Show Continued Stability at 120 Weeks

Eteplirsen-treated boys with DMD who could perform the six-minute walk test showed continued stability in walking distance at week 120 of a phase 2b trial

by Quest Staff on January 15, 2014 - 3:50pm

Update (Jan. 16, 2014): Read Eteplirsen Data Still Strong: Treated Boys with DMD Stable at 120 Weeks for a recap of Sarepta's Jan. 15 presentation.


Boys with Duchenne muscular dystrophy (DMD) participating in a phase 2b extension trial of the experimental exon-skipping drug eteplirsen showed continued stabilization of walking distance at 120 weeks. Sarepta Therapeutics, developer of eteplirsen, announced the findings in a Jan. 15, 2014, press release.

A webcast of Sarepta’s presentation at the J.P Morgan Healthcare Conference will be available on the Sarepta site today at 4:30 p.m. Pacific (7:30 p.m. Eastern).

Your rating: None Average: 5 (3 votes)
MDA cannot respond to questions asked in the comments field. For help with questions, contact your local MDA office or clinic or email publications@mdausa.org. See comment policy